• February 9, 2017

    Bortezomib-Tchaikapharma 3.5 mg powder for solution for injection is Tchaikapharma High Quality Medicines’ newest medicinal product which obtained a Marketing Authorisation by the Bulgarian Drug Agency in the beginning of February 2017. The active substance contained is Bortezomib (as a mannitol boronic ester).

    The medicinal product is subject to medical prescription.

    ATC code: L01XX 32

  • February 2, 2017

    Lidocaine-Tchaikapharma 10 mg and 20 mg solution for injection is Tchaikapharma’s newest product which has obtained a Marketing Authorization issued by the Bulgarian Drug Agency.

    Therapeutic indications:

    • For local anesthesia in surgery, dentistry, urology, cardiology, ophthalmology, otorhinolaryngology and other invasive instrumental investigations.
    • For the treatment of ventricular arrhythmias, including after myocardial infarction and cardiac surgery interventions.

     

    ATC code: C01BB 01, N01BB 02

  • December 23, 2016

    tch_kartichka_eng

  • November 23, 2016

    The renowned business ranking “300 Business Leaders in Bulgaria” for one more year honoured Tchaikapharma High Quality Medicines Inc. as one of the most profitable and influential companies in Bulgaria.

    The ranking’s fifth edition prepared by analysts from ICAP Group brings together the most successful companies in the country for the past year 2015, based on the criterion “Earnings before interest, taxes, depreciation and amortization (EBITDA)”.

    This year Tchaikapharma marked alike a growth on the paramount indicators ‘profit’ (13%) and ‘equity’ (15%). In 2015, EBITDA-profit of the company rose by nearly 11% over the previous year.

    These positive trends determine the high market capitalization of the company amounting to approximately 372.5 million leva (as of 21/11/2016).

  • November 15, 2016

    The newest product of Tchaikapharma High Quality Medicines Inc., which BDA gave a marketing authorisation for, is Cilapenem 500 mg/500 mg powder for infusion solution.

    Each phial contains the following active substances: 530 mg imipenem monohydrate, which is equivalent to 500 mg imipenem anhydrоus, and 532 mg cilastatin sodium, equivalent to 500 mg cilastatin.
    The drug is indicated for the treatment of infections in adults and over 1 year-old children:

    – Complicated intra-abdominal infections;

    – Severe types of pneumonia, including nosocomial pneumonia and ventilator- associated pneumonia;
    – Infections during and after birth;
    – Complicated urinary tract infections;
    – Complicated skin and soft tissue infections

    Tsilapenem is also suitable for the treatment of patients with:
    – Neutropenia and fever, suspected to be due to bacterial infection;
    – Bacteraemia occurring in connection with or presumably associated with any of the above infections.

    The medicinal product is subject to medical prescription.
    ATC code: J01DH 51